

## SPECIALTY QUANTITY LIMIT PROGRAM

### LYNPARZA (olaparib)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

#### II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Lynparza (olaparib) 100 mg tablets	120 per 30 days	Ovarian cancer, breast cancer, and pancreatic cancer: 300 mg orally twice daily  Dose modifications due to adverse reactions, drug interactions, or renal impairment: 100 mg orally twice daily- 250 mg orally twice daily
Lynparza (olaparib) 150 mg tablets	120 per 30 days	

#### III. REFERENCES

1. Lynparza® Tablets [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2019.